HOXC-AS1 and EZH2 Interaction Increase HOXC9 Expression and Promote the Malignant Transformation of Oral Leukoplakia

Overview

Journal J Cancer

Date 2025 Feb 3

PMID 39895798

Authors

Xiaochuan Chen

Jiusong Han

Shuhua Li

Xi Yang

Shuyu Yang

Chenrong Xu

Xueyi Liang

Affiliations

Soon will be listed here.

Abstract

To investigate the role of HOXC9 in the transformation of oral leukoplakia (OLK) to oral squamous cell carcinoma (OSCC) and its effectiveness as a new molecular marker for oral leukoplakia carcinogenesis. : We assessed HOXC9 in OLK and OSCC using immunohistochemistry (IHC). Colony formation and transwell experiment were employed to appraise the function of HOXC9 in the malignant transformation of OLK. ChIP-qPCR, CO-IP, RIP-qPCR, RNA pull down and mass spectrometry were using to evaluate the molecular mechanism of HOXC9. HOXC9 expression was higher in patients with OSCC than in those with OLK, which is associated with increased malignant transformation of OLK. Functional experiments suggested that HOXC9 induces the acquisition of cancer stem cells (CSCs) and epithelial-to-mesenchymal transition (EMT). Subsequently, we found that the HOXC9-mediated malignant phenotype was reversed by HOXC-AS1 depletion. Mechanistically, HOXC-AS1 regulates H3K27me3 methylation and EZH2 as a potential HOXC-AS1-HOXC9 interacting protein. Finally, we found that the 251-619nt nucleotide of HOXC-AS1 competitively binds to EZH2. HOXC-AS1 competitively binds to EZH2, inhibiting its binding to H3 in the HOXC9 promoter region, resulting in a decrease in H3K27me3 and enhanced expression of HOXC9, thereby promoting CSCs and EMT in oral leukoplakia, ultimately leading to malignant transformation into oral squamous cell carcinoma.

References

Pierouli K, Papakonstantinou E, Papageorgiou L, Diakou I, Mitsis T, Dragoumani K . Long non‑coding RNAs and microRNAs as regulators of stress in cancer (Review). Mol Med Rep. 2022; 26(6). DOI: 10.3892/mmr.2022.12878. View

Duan R, Du W, Guo W . EZH2: a novel target for cancer treatment. J Hematol Oncol. 2020; 13(1):104. PMC: 7385862. DOI: 10.1186/s13045-020-00937-8. View

Pinto A, Carames J, Francisco H, Chen A, Azul A, Marques D . Malignant transformation rate of oral leukoplakia-systematic review. Oral Surg Oral Med Oral Pathol Oral Radiol. 2020; 129(6):600-611.e2. DOI: 10.1016/j.oooo.2020.02.017. View

Tang B, Sun R, Wang D, Sheng H, Wei T, Wang L . ZMYND8 preferentially binds phosphorylated EZH2 to promote a PRC2-dependent to -independent function switch in hypoxia-inducible factor-activated cancer. Proc Natl Acad Sci U S A. 2021; 118(8). PMC: 7923384. DOI: 10.1073/pnas.2019052118. View

Okamoto O, Oba-Shinjo S, Lopes L, Nagahashi Marie S . Expression of HOXC9 and E2F2 are up-regulated in CD133(+) cells isolated from human astrocytomas and associate with transformation of human astrocytes. Biochim Biophys Acta. 2007; 1769(7-8):437-42. DOI: 10.1016/j.bbaexp.2007.05.002. View

Shang Q, Peng J, Jiang Y, Qing M, Zhou Y, Xu H . SNAI2 promotes the malignant transformation of oral leukoplakia by modulating p-EMT. Oral Dis. 2022; 29(8):3232-3242. DOI: 10.1111/odi.14321. View

Zhuang Z, Xie N, Hu J, Yu P, Wang C, Hu X . Interplay between ΔNp63 and miR-138-5p regulates growth, metastasis and stemness of oral squamous cell carcinoma. Oncotarget. 2017; 8(13):21954-21973. PMC: 5400637. DOI: 10.18632/oncotarget.15752. View

Liu W, Zhou Z, Yang X, Shi H . Whether cancer stem cell markers can serve as the markers for malignant progression of oral potentially malignant disorders. Oral Dis. 2021; 28(7):2057-2058. DOI: 10.1111/odi.14088. View

Xuan F, Huang M, Liu W, Ding H, Yang L, Cui H . Homeobox C9 suppresses Beclin1-mediated autophagy in glioblastoma by directly inhibiting the transcription of death-associated protein kinase 1. Neuro Oncol. 2015; 18(6):819-29. PMC: 4864258. DOI: 10.1093/neuonc/nov281. View

10.

Liu Y, Yang Q . The roles of EZH2 in cancer and its inhibitors. Med Oncol. 2023; 40(6):167. PMC: 10162908. DOI: 10.1007/s12032-023-02025-6. View

11.

de Moura Aguiar G, Ramao A, Placa J, Simoes S, Scaraboto N, Freitas-Castro F . Upregulation of HOX genes promotes cell migration and proliferation in head and neck squamous cell carcinoma. Tumour Biol. 2021; 43(1):263-278. DOI: 10.3233/TUB-211525. View

12.

Zheng M, Cao M, Luo X, Li L, Wang K, Wang S . EZH2 promotes invasion and tumour glycolysis by regulating STAT3 and FoxO1 signalling in human OSCC cells. J Cell Mol Med. 2019; 23(10):6942-6954. PMC: 6787444. DOI: 10.1111/jcmm.14579. View

13.

Liang X, Deng M, Zhang C, Ping F, Wang H, Wang Y . Combined class I histone deacetylase and mTORC1/C2 inhibition suppresses the initiation and recurrence of oral squamous cell carcinomas by repressing SOX2. Cancer Lett. 2019; 454:108-119. DOI: 10.1016/j.canlet.2019.04.010. View

14.

Zhang Y, Yuan J, Zhang L, Chen C, Wang Y, Zhang G . Coupling of H3K27me3 recognition with transcriptional repression through the BAH-PHD-CPL2 complex in Arabidopsis. Nat Commun. 2020; 11(1):6212. PMC: 7718874. DOI: 10.1038/s41467-020-20089-0. View

15.

Soureas K, Papadimitriou M, Panoutsopoulou K, Pilala K, Scorilas A, Avgeris M . Cancer quiescence: non-coding RNAs in the spotlight. Trends Mol Med. 2023; 29(10):843-858. DOI: 10.1016/j.molmed.2023.07.003. View

16.

Huang J, Gou H, Yao J, Yi K, Jin Z, Matsuoka M . The noncanonical role of EZH2 in cancer. Cancer Sci. 2021; 112(4):1376-1382. PMC: 8019201. DOI: 10.1111/cas.14840. View

17.

Wang J, He Z, Liu X, Xu J, Jiang X, Quan G . LINC00941 promotes pancreatic cancer malignancy by interacting with ANXA2 and suppressing NEDD4L-mediated degradation of ANXA2. Cell Death Dis. 2022; 13(8):718. PMC: 9385862. DOI: 10.1038/s41419-022-05172-2. View

18.

Yao Y, Liu Y, Jin F, Meng Z . LINC00662 Promotes Oral Squamous Cell Carcinoma Cell Growth and Metastasis through miR-144-3p/EZH2 Axis. Yonsei Med J. 2021; 62(7):640-649. PMC: 8236341. DOI: 10.3349/ymj.2021.62.7.640. View

19.

Cerqueira J, Pontes F, Santos-Silva A, Almeida O, Costa R, Fonseca F . Malignant transformation of oral leukoplakia: a multicentric retrospective study in Brazilian population. Med Oral Patol Oral Cir Bucal. 2020; 26(3):e292-e298. PMC: 8141311. DOI: 10.4317/medoral.24175. View

20.

Hanaki S, Shimada M . Targeting EZH2 as cancer therapy. J Biochem. 2021; 170(1):1-4. DOI: 10.1093/jb/mvab007. View